LSA
ADMS

Leonteq Securities AG’s Adamas Pharmaceuticals ADMS Stock Holding History

Leonteq Securities AG’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30,000
Closed -$158K – 1250
2021
Q2 		$158K Hold
30,000
– – 0.01% 617
2021
Q1 		$144K Hold
30,000
– – 0.01% 603
2020
Q4 		$130K Buy
+30,000
New +$128K 0.01% 635

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Leonteq Securities AG's ADMS Position: Q3 2021 in Review

Leonteq Securities AG sold out of Adamas Pharmaceuticals (ADMS) in Q3 2021, closing a stake of 30,000 shares — an estimated $158K sold.

Leonteq Securities AG first reported a position in ADMS in Q4 2020 and held it in 3 quarters. The position peaked at $158K in Q2 2021. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2021.

  • Leonteq Securities AG reported no remaining Adamas Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Leonteq Securities AG sold 30,000 Adamas Pharmaceuticals shares in Q3 2021, an estimated $158K.
  • Leonteq Securities AG first reported a position in Adamas Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Leonteq Securities AG's Adamas Pharmaceuticals position peaked at $158K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2021.

Based on Leonteq Securities AG's 13F filing for Q3 2021, filed 26 Mar 2026.